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Abstract
Reboxetine is a selective noradrenaline reuptake inhibi-
tor, whereas mirtazapine acts as an antagonist at norad-
renergic ·2, serotonin (5-HT2), 5-HT3 and histamine H1
receptors. In a former study we could demonstrate an
inhibitory impact of mirtazapine on cortisol secretion. In
the present investigation, the influence of combined
administration of 15 mg mirtazapine and 4 mg reboxe-
tine on the cortisol (COR), adrenocorticotropin (ACTH),
growth hormone (GH), and prolactin (PRL) secretion was
examined in 12 healthy male subjects, compared to
reboxetine alone (4 mg). In a randomized order, the sub-
jects received reboxetine (4 mg) alone or the combina-
tion of reboxetine (4 mg) and mirtazapine (15 mg) at
8:00 a.m. on two different days. After insertion of an
intravenous catheter, blood samples were drawn 1 h
prior to the administration of single reboxetine or the
combination (reboxetine and mirtazapine), at time of
administration, and during the time of 5 h thereafter in
periods of 30 min. Serum concentrations of COR, GH,
and PRL as well as plasma levels of ACTH were deter-
mined in each blood sample by means of double anti-
body RIA, fluoroimmunoassay and chemiluminescence
immunometric assay methods. The area under the curve
(AUC) was used as parameter for the COR, ACTH, GH,
and PRL response. For statistical evaluation, the Wilcox-
on signed-ranks test was performed. There was a pro-
nounced stimulation of COR, ACTH, GH, and PRL con-
centrations after single administration of reboxetine.
When reboxetine was given in combination with mirta-
zapine, a significant reduction of the COR, ACTH, and
PRL stimulation was observed whereas GH secretion
patterns remained unchanged, compared to single ad-
ministration of reboxetine. Apparently, the stimulatory
effects of reboxetine on pituitary hormone secretion via
noradrenergic mechanisms are counteracted in part by
the ·2-blocking properties of mirtazapine and its inhibito-
ry influence on cortisol secretion.
Copyright © 2004 S. Karger AG, Basel
Introduction
The neuroendocrine challenge paradigm is based on
the involvement of monoamine pathways in the control of
anterior pituitary hormone secretion [1, 2] and has been
described extensively [3–5]. Psychotropic drugs with dif-
ferent effects on the central neurotransmitter system have
distinct effects on the anterior pituitary hormone secre-
tion and can be characterized by certain pharmacoendo-
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Table 1. Influence of acute administration
of antidepressant agents on
neurotransmitter reuptake in vitro
(IC50 values) and GH, PRL, and COR
secretion in man, modified according
to Hyttel [6, 7]
NA 5-HT DA GH PRL COR
0.9 210 –* desipramine 25 mg i.v. +++ ++ +++
desipramine 100 mg p.o. +++ + +++
14 35 –* imipramine 100 mg p.o. ++ +++ +++
0.6 0.2 2.8 venlafaxine 75 mg p.o. + ++ +++
1.1 –* –* D-oxaprotiline 75 mg i.v. +++ 0 +++
–* –* –* L-oxaprotiline 75 mg p.o. 0 0 0
8.0 –* –* maprotiline [10, 11] 50 mg p.o. ++ 0 n.a.
6.6 830 48 nomifensine 200 mg p.o. ++ – n.a.
24 1.5 –* clomipramine 25 mg i.v. ++ +++ +++
clomipramine 100 mg p.o. ++ + +
–* 2.4 –* indalpine 25 mg i.v. 0 ++ +++
370 6.8 –* fluoxetine [12, 13] 80 mg p.o. 0 0 +++
620 3.8 –* fluvoxamine 100 mg p.o. n.a. n.a. +++
–* 1.8 –* citalopram 20 mg i.v. 0 +++ +++
IC50 values (nM) indicated; –* = IC50 11,000 nM; NA = noradrenaline; 5-HT = serotonin;
DA = dopamine; +++ = strong stimulation; ++ = moderate stimulation; + = slight stimulation;
– = inhibition; 0 = no significant effect; n.a. = not available.
crinological profiles (table 1) [4, 6–15]. Antidepressants
which primarily act via noradrenaline (NA) reuptake
inhibition (e.g. desipramine) stimulate growth hormone
(GH) secretion [16], whereas serotonin (5-HT)-reuptake-
inhibiting antidepressants (e.g. indalpine, chlomipram-
ine) are characterized by prolactin (PRL) stimulation [4].
Cortisol (COR) secretion can acutely be increased by anti-
depressants with both NA or 5-HT reuptake inhibition;
the stimulatory effects of antidepressants on COR secre-
tion are mediated via stimulation of the adrenocorticotro-
pin (ACTH) output of the pituitary gland [4].
Mirtazapine that does not inhibit the reuptake of NA
or 5-HT but acts as an antagonist at ·2-, 5-HT2 and 5-HT3
receptors [17] displays a special pharmacoendocrinologi-
cal profile, since it acutely inhibits COR secretion [18]
and ACTH release [19], probably due to central 5-HT2
and/or H1 receptor antagonism and acute reduction of
corticotropin-releasing hormone (CRH) and vasopressin
release. Mirtazapine enhances NA release by blocking ·2-
autoreceptors [17]. Serotonergic neurotransmission is also
increased by mirtazapine, especially in the hippocampus,
via two synergistic mechanisms: an increase of 5-HT cell
firing and a blockade of ·2-adrenergic heteroreceptors at
the 5-HT nerve terminals [20, 21]. In addition, mirtaza-
pine is an antihistaminergic agent with a high affinity for
histamine H1 receptors [22] and has only few anticholin-
ergic side effects. Average peak plasma concentrations
(Cmax) are achieved 2 h after oral dosing and the elimina-
tion half-life is in the range between 20 and 40 h [23].
Reboxetine is a novel antidepressant drug that selec-
tively inhibits NA reuptake (IC50 values: NA reuptake
8 nM; 5-HT reuptake 1,070 nM; functional selectivity 5-
HT/NA 130; DA reuptake 110,000 nM) [24]. Unlike
desipramine or imipramine, reboxetine has only weak
affinity (Ki 11,000 nmol/l) for muscarinergic, histaminer-
gic H1, adrenergic ·1, and dopaminergic D2 receptors
[24]. Moreover, reboxetine is rapidly absorbed in man
(tmax about 2 h) with a terminal elimination half-life of
13 h and has linear pharmacokinetics in young, healthy
males for single doses of 1–5 mg [25]. In clinical studies,
reboxetine has been shown to have a favorable tolerability
and safety profile with only few side effects such as dry
mouth, constipation, increased sweating, insomnia, uri-
nary hesitancy or retention, and tachycardia [26, 27]. Fur-
thermore, in placebo-controlled and active comparator
trials, the antidepressant efficacy of reboxetine has been
demonstrated [28].
Studies of our research group concerning the endocri-
nological effects of single administration of 4 mg reboxe-
tine in healthy volunteers revealed significantly stimula-
tory effects of reboxetine on COR, ACTH, GH and PRL
secretion compared to placebo [29]. In the present investi-
gation, the influence of combined oral administration of
15 mg mirtazapine and 4 mg reboxetine on the COR,
ACTH, GH, and PRL secretion was examined in 12
healthy male subjects, compared to reboxetine alone
(4 mg). Because reboxetine selectively inhibits the NA
reuptake, we tried to elucidate the question whether mir-
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tazapine is able to antagonize the endocrinological effects
of reboxetine by its ·2-blocking properties and its inhibi-
tory influence on COR secretion. In particular with
respect to COR and ACTH release, the questions to be
answered in the present study may be of clinical interest
since it has been hypothesized that hyperactivity of the
hypothalamic-pituitary-adrenocortical (HPA) axis con-
tributes to the pathophysiology of depression [30] and the
reduction of HPA axis hyperactivity by antidepressant
drugs plays a role in their antidepressant efficacy [31].
The study was designed as a pre-study in healthy volun-
teers to further investigate in depressed patients the possi-
ble interrelationship between fast abolition of COR stim-
ulatory effects of reuptake-inhibiting antidepressants and
presumptive early onset of antidepressant efficacy when
mirtazapine is given simultaneously for several weeks.
Therefore, we decided not to use specific ·2-blockers such
as yohimbine in the present study, which are usually not
used in treatment of depressive disorder.
Subjects and Methods
Study Population and Study Design
12 healthy male subjects of normal weight, age 20–35 years, were
included upon receipt of their informed consent, following a clinical
examination (psychiatric and medical history, physical examination)
and establishment of normal laboratory parameters (Hb, K+, Na+,
glutamate oxalo-acetate transaminase (GOT), glutamate pyruvate
transaminase (GPT), Á-GT, blood glucose, bilirubin, serum creati-
nine, heart rate, electrocardiogram and electroencephalogram). Alco-
hol abstinence 24 h prior to each experiment and abstinence from
medication beginning 4 weeks before the study were mandatory.
Each subject took part twice in the trial; in a randomized order
the volunteers received reboxetine (4 mg) alone or the combination
of reboxetine (4 mg) and mirtazapine (15 mg) at 8:00 a.m. on two
different days. The interval between these two conditions was at least
1 week, at most 3 weeks. Randomization was performed by an on-
line computer randomization program (http://www.randomiza-
tion.com). The volunteers received two tablets on each study day (re-
boxetine 4 mg and placebo [’dummy’ tablet]; reboxetine 4 mg and
mirtazapine 15 mg). The study drugs were dispensed as film-coated
tablets, which were identical in all aspects of their appearance and
were kindly supplied by the Pharmacia & Upjohn Company. On
each study day, at 7:00 a.m. an intravenous catheter was inserted into
the antecubital vein and kept open with physiological saline solution.
The subjects rested in bed throughout the experiments (up to t =
300 min). At t = –60 min (7:00 a.m.), t = 0 min (8:00 a.m.; administra-
tion of placebo or reboxetine), and at intervals of 30 min thereafter up
to t = 300 min (1:00 p.m.), blood was drawn. Moreover, blood pres-
sure, heart rate and side effects which occurred in the course of the
experiment were recorded every 30 min in the study protocol. Since
food intake and leptin levels have an impact on the anterior pituitary
hormone secretion [32, 33], subjects fasted from completion of the
evening meal the day before until conclusion of the experiment to
achieve standardized nutritional conditions on each study day.
The study was carried out according to the fifth revision of the
Declaration of Helsinki [34] and had been approved by an ethics
committee.
Endocrinological Measurements
Serum and plasma samples were separated by centrifugation as
soon as possible, frozen at –80°C, and stored for the assay of hor-
mone concentrations. Serum concentrations of COR, GH, and PRL
and plasma concentrations of ACTH were determined in each blood
sample. COR, GH, and PRL levels were determined by double-anti-
body radioimmunoassay (RIA) and fluoroimmunoassay methods.
The sensitivity (‘minimal detectable dose’) of the commercially avail-
able immunoassay kits was approximately 6.1 nmol/l for the COR
RIA (Diagnostic Products Corporation®); 4.5 pmol/l for the GH
fluoroimmunoassay (DELFIA® hGH), and 1.74 pmol/l for the PRL
fluoroimmunoassay (DELFIA® Prolactin). The specificity was very
high for the immunoassays with an extremely low cross-reactivity to
other natural hormones; the percental cross-reactivity to other natu-
rally occurring steroids in quality control tests (apparent concentra-
tions related to the amount added in the experiment) was up to 6.8%
for the COR RIA (although some steroids exhibit slight cross-reactiv-
ity, their normal physiological concentrations are low compared to
COR so as not significantly interfere in the double antibody cortisol
procedure); 0.1% for the GH fluoroimmunoassay, and !0.01% for
the PRL fluoroimmunoassay. The total variation (% CV) was 6.6%
for the COR RIA; 3.9% for the GH fluoroimmunoassay, and 2.7%
for the PRL fluoroimmunoassay. ACTH was measured using a
chemiluminescence immunometric assay (Nichols, San Juan Capis-
trano, Calif., USA); the lower detection limit of this assay is
0.11 pmol/l, intra- and interassay CVs are below 4 and 7%, respec-
tively.
Data Analysis
In addition to the descriptive and graphical evaluation of the
mean curves of the hormonal concentrations, the areas under the
curve (AUCs, 0–300 min) were calculated according to Simpson [35],
representing the total COR, ACTH, GH, and PRL secretion follow-
ing oral administration of reboxetine alone (4 mg) or the combina-
tion of reboxetine (4 mg) and mirtazapine (15 mg). For statistical
comparison of the mean AUC values after single and combined
administration, the Wilcoxon signed-ranks test was performed. As a
nominal level of significance, alpha = 0.05 was accepted. In the ‘Re-
sults’ section, mean values and standard errors of mean (SEM) are
indicated.
Results
COR and ACTH Secretion
After single administration of reboxetine (4 mg), a
remarkable increase of serum COR and plasma ACTH
concentrations occurred (fig. 1) (single administration:
COR AUC0–300: 127,893.20 B 8,125.75 nmol/l ! min;
ACTH AUC0–300: 2,385.68 B 387.19 pmol/l ! min).
After combined administration of reboxetine (4 mg) and
mirtazapine (15 mg), both the COR and ACTH stimula-
tion were less pronounced (combined administration:
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Fig. 1. Means B SEM of cortisol (a) and
ACTH (b) concentrations after single ad-
ministration of 4 mg reboxetine and after
combined administration of 4 mg reboxetine
and 15 mg mirtazapine in 12 healthy male
subjects. p ! 0.05 and p ! 0.01 indicate a sig-
nificant or a highly significant difference,
respectively.
COR AUC0–300: 95,348.74 B 8,141.30 nmol/l ! min;
ACTH AUC0–300: 1,656.45 B 215.26 pmol/l ! min). The
Wilcoxon test revealed significant differences both for
COR and ACTH secretion (COR: Z = –3.059; p = 0.002;
ACTH: Z = –2.510; p = 0.012).
GH Secretion
GH stimulation was comparable after both single ad-
ministration of reboxetine (4 mg) and combined adminis-
tration of reboxetine (4 mg) and mirtazapine (fig. 2)
(single administration: GH AUC0–300 = 56,026.59 B
15,594.87 pmol/l ! min; combined administration: GH
AUC0–300 = 48,425.84 B 12,244.22 pmol/l ! min). No
statistical difference could be demonstrated (Wilcoxon
test: Z = –0.549; p = 0.583).
PRL Secretion
A pronounced PRL stimulation after single admin-
istration of reboxetine (4 mg) was observed (fig. 2)
(single administration: PRL AUC0–300 = 113,961.60 B
10,280.44 pmol/l ! min). When reboxetine (4 mg) and
mirtazapine (15 mg) were given simultaneously, this PRL
stimulation was markedly diminished (combined admin-
istration: PRL AUC0–300 = 81,292.30 B 7,249.30 pmol/l
! min). Using the Wilcoxon signed-ranks test, there was a
highly significant difference (Z = –2.981; p = 0.003).
Side Effects
After single administration of reboxetine, 3 volunteers
reported dry mouth to a moderate degree, in 4 subjects
mild agitation occurred, and 3 participants complained of
slightly to moderately increased sweating. When reboxe-
tine and mirtazapine were given simultaneously, dry
mouth and increased sweating happened in 2 subjects,
respectively. However, all volunteers reported feeling
moderately to markedly sedated after additional adminis-
tration of mirtazapine. The sedation began 0.5 or 1 h after
the combination of reboxetine and mirtazapine was given
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Fig. 2. Means B SEM of GH (a) and PRL
(b) concentrations after single adminis-
tration of 4 mg reboxetine and after com-
bined administration of 4 mg reboxetine and
15 mg mirtazapine in 12 healthy male sub-
jects. p ! 0.01 indicates a highly significant
difference.
and lasted up to the end of the measurement period in
most cases. No clinically relevant changes were observed
in blood pressure and heart rate during both treatment
conditions with the exception of one volunteer who
showed increased heart rate and developed tachycardia
(heart rate greater than 100 beats per minute) after a sin-
gle administration of reboxetine.
Discussion
COR and ACTH Secretion
As already demonstrated by investigations of our re-
search group concerning the endocrinological effects of
single administration of 4 mg reboxetine in healthy volun-
teers, reboxetine significantly stimulates COR, ACTH,
GH and PRL secretion compared to placebo [29]. This is
in line with a study of Piacentini et al. [36] who reported
significantly elevated COR, ACTH and PRL responses to
physical exercises in 7 healthy well-trained male cyclists
after treatment with 2 ! 4 mg reboxetine in comparison
to placebo and is also in accordance with an investigation
of Hennig et al. [37] who found a reboxetine-induced
stimulation of salivary COR in healthy male subjects, par-
ticularly in those scoring high on subclinical depression.
In the present study, the stimulatory effects of single
administration of reboxetine (4 mg) on COR, ACTH, and
PRL secretion, but not on GH release were significantly
reduced after combined administration of reboxetine
(4 mg) and mirtazapine (15 mg).
Animal studies suggest that activation of ·1-adreno-
ceptors stimulates the secretion of CRH and vasopressin
[38–42], whereas ·2-adrenergic mechanisms play rather a
modulatory inhibitory role with regard to hypothalamic-
pituitary-adrenocortical (HPA) axis activity [43], and
have been shown to inhibit ACTH secretion during stress
in dogs [44, 45]. In humans, the desipramine-induced
COR stimulation is reduced by simultaneous administra-
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tion of the ·1-blocker prazosin and increased if yohim-
bine, an ·2-adrenoceptor, is given at the same time where-
as the ß-adrenoceptor blocker propranolol does not have
any influence [46]. Therefore one can assume that the
increased ACTH and COR release after single adminis-
tration of the selective NA reuptake inhibitor reboxetine
observed in our study is mediated via activation of hypo-
thalamic ·1-adrenoceptors, thereby stimulating CRH
and/or vasopressin output.
In former studies we could demonstrate an acute inhib-
itory effect of single administration of mirtazapine on
COR and ACTH secretion in healthy subjects, presum-
ably due to blockade of central 5-HT2 and histamine H1
receptors [18, 19]. In our study reboxetine stimulates
ACTH and COR secretion probably via activation of
hypothalamic ·1-adrenoceptors. Mirtazapine does not
block these receptors but seems to inhibit ACTH and
COR release via central 5-HT2 and H1 antagonism.
Therefore, mirtazapine markedly decreases the reboxe-
tine-induced ACTH and COR stimulation when given
simultaneously. However our study is methodologically
limited by the fact that a cross-over design was not used,
and thus did not allow to detect drug interaction effects,
which are nevertheless rather unlikely since reboxetine
and mirtazapine follow different kinds of mechanisms of
action.
It has been suggested that antidepressants with reup-
take-inhibiting properties may act in part through gradual
normalization of hypothalamic-pituitary-adrenocortical
(HPA) system hyperactivity [30, 31, 47]. In contrast to
mirtazapine, reuptake-inhibiting antidepressants such as
reboxetine or others acutely stimulate COR and ACTH
secretion in both healthy subjects [4, 29] and depressed
patients [48–50] and may gradually normalize HPA axis
hyperactivity in depressed patients via up-regulation of
glucocorticoid receptor mRNA levels and enhancement
of glucocorticoid receptor function [51]. This upregula-
tion takes several weeks and may be triggered by the acute
stimulatory effects of reuptake inhibitors on COR and
ACTH release. However, mirtazapine acutely tunes down
HPA axis activity via direct pharmacoendocrinological
effects and inhibition of hypothalamic CRH and/or vaso-
pressin release. It has not been investigated so far whether
mirtazapine treatment enhances mRNA levels of the glu-
cocorticoid receptor in depressed patients. Nevertheless,
the acute reduction of HPA axis hyperactivity by mirtaza-
pine may contribute to its antidepressant efficacy or may
at any rate accelerate the amelioration of symptoms in
depressed patients. In fact, several studies suggest a nota-
bly early onset of antidepressant action in depressed
patients treated with mirtazapine [52–55]. Since the re-
boxetine-induced COR and ACTH stimulation is reduced
but not abolished when given simultaneously with mirta-
zapine, one may speculate whether combined administra-
tion of reuptake inhibitors such as reboxetine (enhance-
ment of glucocorticoid receptor function for several
weeks) and mirtazapine (direct inhibition of hypothalam-
ic CRH and/or vasopressin release) effectively reduces
HPA axis hyperactivity in depression via two different
mechanisms and is suitable to improve or accelerate anti-
depressant efficacy.
GH Secretion
In the present investigation, GH release was markedly
increased after single administration of reboxetine. How-
ever, a similar GH stimulation was also observed after
combined administration of reboxetine and mirtazapine.
There is evidence from animal and human studies that
the reboxetine-induced GH stimulation is mediated via
activation of hypothalamic ·2-receptors. GH release from
pituitary somatotropes is stimulated by growth hor-
mone-releasing hormone (GHRH) and inhibited by so-
matostatin, which are both modulated by the central
adrenergic system. Activation of ·2-adrenoceptors stimu-
lates the secretion of GHRH from rat hypothalamic slices
in vitro [56, 57], and pretreatment with antiserum to
GHRH abolishes the GH response to the ·2-agonist cloni-
dine in rats [58]. It is likely that activation of postsynaptic
·2-adrenoceptors may, in addition, inhibit the secretion
of somatostatin [59]. Clonidine does not stimulate GH
release directly from the rat pituitary [60]. In analogy to
the data obtained in rats, clonidine also stimulates GH
secretion in humans [61, 62]. Moreover, there is evidence
from human studies that the action of clonidine is exerted
via both stimulation of GHRH [60] and inhibition of
somatostatin [63, 64].
An inhibitory action of catecholamines on GH secre-
tion appears to be exerted via ß-adrenoceptors. Adminis-
tration of the ß-blocker propranolol has no effect on the
GH output under basal conditions [65], but the ß-blocker
propranolol increases GH stimulation after administra-
tion of the NA reuptake inhibitor desipramine [66], indi-
cating an inhibitory influence of ß-receptors on GH
release. Therefore, the most plausible explanation for the
reboxetine-induced GH stimulation seen in our study is
noradrenergic enhancement of GHRH release and inhibi-
tion of somatostatin output via hypothalamic ·2-adreno-
ceptors that overcome the inhibitory impact of ß-recep-
tors on GH secretion.
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Surprisingly in our study the reboxetine-induced GH
stimulation was not reduced by simultaneous administra-
tion of the ·2-blocker mirtazapine. Since the ·2-blocker
yohimbine has been demonstrated to significantly reduce
GH stimulation after administration of the NA reuptake
inhibitor desipramine in man [66], one would rather
expect similar inhibitory effects of mirtazapine on GH
stimulation after reboxetine. However, it has to be taken
into account that presynaptic and postsynaptic ·2-recep-
tors exert different effects on noradrenergic neurotrans-
mission. It has been observed that the ·2-blocker idazox-
an seems to cause a modest increase of GH in man [67].
According to Schmidt and his colleagues [67], the expla-
nation for this result is that idazoxan has a higher affinity
for presynaptic ·2-receptors (leading to an increased NA
release) than for postsynaptic ·2-receptors (blocking the
stimulatory effects of NA on GH secretion); thus, the
enhanced NA release overcomes the moderate blockade
of postsynaptic ·2-receptors, thereby increasing GH secre-
tion. This interplay between pre- and postsynaptic block-
ade of ·2-receptors may also be responsible for our obser-
vation that simultaneous administration of the ·2-blocker
mirtazapine at a dosage of 15 mg does not have any
impact on the reboxetine-induced GH stimulation. Ob-
viously, the presumed blockade of postsynaptic ·2-recep-
tors after 15 mg mirtazapine is compensated by the
enhancement of NA release via antagonism of presynap-
tic ·2-receptors.
PRL Secretion
In the present investigation, reboxetine markedly en-
hanced PRL secretion in healthy male subjects. Since
reboxetine is a highly selective NA reuptake inhibitor, this
PRL stimulation can only be explained by noradrenergic
mechanisms. Indeed, in several animal and human stud-
ies a possible adrenergic control of PRL release has been
suggested. In rat studies, infusion of adrenaline into the
preoptic hypothalamic area or into the lateral cerebral
ventricle enhanced PRL output and the effect was
blocked by phentolamine [68, 69]. In humans, intrave-
nous infusion of the ·1-agonist methoxamine that can
cross the blood-brain barrier stimulates PRL secretion
[70]. Most human studies provide no clear evidence for an
important role of ·-adrenoceptors in the control of PRL
secretion in man [71–73]. Moreover, in healthy human
volunteers under basal conditions, secretion of PRL is
unaffected in most studies by the ·2-antagonists yohim-
bine, idazoxan and atipremazole [74–77], or by the ·2-
agonists clonidine and guanfacine [61, 78–81]. However,
there are also investigations suggesting PRL stimulation
by clonidine in healthy controls and depressed patients
[82] and PRL stimulation by yohimbine in recently detox-
ified alcoholics [81].
In our study, simultaneous administration of mirtaza-
pine significantly reduced PRL stimulation after reboxe-
tine. Mirtazapine is thought to stimulate 5-HT1A-recep-
tors in an indirect manner by enhancement of serotoner-
gic cell firing and by increasing 5-HT release, whereas
5-HT2 and 5-HT3 receptors are directly blocked [20, 21].
In contrast to direct 5-HT1A-receptor agonists such as
ipsapirone or buspirone [83] and 5-HT-reuptake inhibi-
tors such as indalpine or chlorimipramine [4] that stimu-
late PRL release, indirect serotonergic agonists such as
mirtazapine fail to cause PRL stimulation [18, 19]. The
significant reduction of reboxetine-induced PRL stimula-
tion after simultaneous administration of the ·2-blocker
mirtazapine suggests a role of ·2-receptors in the enhance-
ment of PRL release after single administration of reboxe-
tine. However, conflicting results in the literature con-
cerning noradrenergic regulation of PRL secretion do not
allow an accurate explanation for this observation.
Side Effects
Taken together, both single administration of 4 mg
reboxetine and combined dosage of 4 mg reboxetine and
15 mg mirtazapine were quite well tolerated. No medical
intervention was necessary. Slight-to-moderate side ef-
fects such as dry mouth, mild agitation, increased sweat-
ing or slight tachycardia which could be observed in some
but not all volunteers are in accordance with the known
tolerability profile of reboxetine which is nevertheless
favorable [26, 27]. The acute sedative effects after com-
bined administration which could be demonstrated in
each subject can be attributed to mirtazapine and its
antagonistic impact on histamine H1 receptors [22].
Acknowledgments
This study was supported by Pharmacia & Upjohn. The authors
wish to thank Angela Johnson for expert technical assistance.
Mirtazapine Decreases Hormone
Stimulation by Reboxetine
Neuroendocrinology 2004;79:54–62 61
References
1 Müller EE, Nistico G, Scapagni V: Chapter 3;
in Müller EE (ed): Neurotransmitters and An-
terior Pituitary Function. New York, Academ-
ic Press, 1977, pp 212–232.
2 Tuomisto J, Mannisto P: Neurotransmitter
regulation of anterior pituitary hormones.
Pharmacol Rev 1985;37:249–332.
3 Checkley SA: Neuroendocrine tests of mono-
amine function in man: A review of basic theo-
ry and its application to the study of depressive
illness. Psychol Med 1980;10:35–53.
4 Laakmann G: Psychopharmaco-endocrinology
and depression research. Monogr Gesamtgeb
Psychiatr Psychiatry Ser 1988;46:1–220.
5 Yatham LN, Steiner M: Neuroendocrine
probes of serotonergic function: A critical re-
view. Life Sci 1993;53:447–463.
6 Hyttel J: Citalopram-pharmacological profile
of a specific serotonin uptake inhibitor with
antidepressant activity. Prog Neuropsycho-
pharmacol Biol Psychiatry 1982;6:277–295.
7 Hyttel J: Pharmacological characterization of
selective serotonin reuptake inhibitors (SSRIs).
Int Clin Psychopharmacol 1994;9(suppl 1):
S19–S26.
8 Nutt D, Middleton H, Franklin M: The neu-
roendocrine effects of oral imipramine. Psy-
choneuroendocrinology 1987;12:367–375.
9 Daffner C, Laakmann G, Voderholzer U, Haag
C, Baghai T, Kolmsee S, Schröder U, Munz T:
The neuroendocrine effects of venlafaxine in
healthy subjects. Hum Psychopharmacol 1996;
11:1–9.
10 Sawa Y, Odo S, Nakazawa T: Growth hormone
secretion by tricyclic and non-tricyclic antide-
pressants in healthy volunteers and depres-
sives. Adv Biosci 1982;40:309–315.
11 Koizumi K, Aono T, Tanazawa O: The acute
effects of antidepressants, maprotiline and
amoxaprine on serum prolactin and gonadotro-
pin levels in normal woman. Asia Oceania J
Obstet Gynaecol 1986;12:517–521.
12 Von Bardeleben U, Steiger A, Gerken A, Hols-
boer F: Effects of fluoxetine upon pharmacoen-
docrine and sleep-EEG parameters in normal
controls. Int Clin Psychopharmacol 1989;
4(suppl 1):1–5.
13 Petraglia F, Facchinetti F, Martignoni E, Nap-
pi G, Volpe A, Genazzani AR: Serotonergic
agonists increase plasma levels of beta-endor-
phin and beta-lipotropin in humans. J Clin
Endocrinol Metab 1984;59:1138–1142.
14 Skene DJ, Bojkowski CJ, Arendt J: Compari-
son of the effects of acute fluvoxamine and
desipramine administration on melatonin and
cortisol production in humans. Br J Clin Phar-
macol 1994;37:181–186.
15 Seifritz E, Baumann P, Müller MJ, Annen O,
Amey M, Hemmeter U, Hatzinger M, Chardon
F, Holsboer-Trachsler E: Neuroendocrine ef-
fects of a 20-mg citalopram infusion in healthy
males: A placebo-controlled evaluation of cita-
lopram as 5-HT function probe. Neuropsycho-
pharmacology 1996;14:253–363.
16 Laakmann G, Schön HW, Wittmann M: Desi-
pramine and growth hormone Secretion. Lan-
cet 1981;ii:996.
17 De Boer T: The effects of mirtazapine on cen-
tral noradrenergic and serotonergic neurotrans-
mission. Int Clin Psychopharmacology 1995;
10(suppl 4):S19–S23.
18 Laakmann G, Schüle C, Baghai T, Waldvogel
E: Effects of mirtazapine on growth hormone
prolactin and cortisol secretion in healthy male
subjects. Psychoneuroendocrinology 1999;24:
769–784.
19 Schüle C, Baghai T, Bidlingmaier M, Stras-
burger C, Laakmann G: Endocrinological ef-
fects of mirtazapine in healthy volunteers. Prog
Neuropsychopharmacol Biol Psychiatry 2002;
26:1253–1261.
20 De Boer T, Nefkens F, Van Helvoirt A: Differ-
ences in modulation of noradrenergic and sero-
tonergic transmission by the alpha-2 adreno-
ceptor antagonists mirtazapine, mianserin and
idaxozan. J Pharmacol Exp Ther 1996;277:
852–860.
21 Haddjeri N, Blier P, De Montigny C: Effect of
the alpha-2 adrenoceptor antagonist mirtaza-
pine on the 5-hydroxytryptamin system in the
rat brain. J Pharmacol Exp Ther 1996;277:
861–871.
22 De Boer T, Maura G, Raiteri M: Neurochemi-
cal and autonomic pharmacological profiles of
the 6-aza-analogue of mianserin mirtazapine
and its enantiomers. Neuropharmacology
1988;27:399–408.
23 Timmer CJ, Paanaker JE, Vrijmed-de-Vries
M: Mirtazapine pharmacokinetics with two
dosage regimens and two pharmaceutical for-
mulations. Pharm Res 1997;14:98–102.
24 Wong EHF, Sonders MS, Amara SG, Tinholt
PM, Piercy MFP, Hoffmann WP, Hyslop DK,
Franklin S, Porsolt RD, Bonsignori A, Carfa-
gna N, McArthur RA: Reboxetine: A pharma-
cologically potent selective and specific norepi-
nephrine reuptake inhibitor. Biol Psychiatry
2000;47:818–829.
25 Dostert P, Benedetti MS, Poggesi I: Review of
the pharmacokinetics and metabolism of re-
boxetine a selective noradrenaline reuptake in-
hibitor. Eur Neuropsychopharm 1997;7(suppl
1):S23–S35.
26 Tanum L: Reboxetine: Tolerability and safety
profile in patients with major depression. Acta
Psychiatr Scand 2000;101(suppl 402):S37–S40.
27 Berzewski H, Van Moffaert M, Cagiano CA:
Efficacy and tolerability of reboxetine com-
pared with imipramine in a double-blind study
in patients suffering from major depressive epi-
sodes. Eur Neuropsychopharm 1997;7(suppl
1):S37–S47.
28 Schatzberg AF: Clinical efficacy of reboxetine
in major depression. J Clin Psychiatry 2000;61
(suppl 10):S31–S38.
29 Schüle C, Baghai T, Schmidbauer S, Bidling-
maier M, Strasburger CJ, Laakmann G: Re-
boxetine acutely stimulates cortisol, ACTH,
growth hormone and prolactin secretion in
healthy male subjects. Psychoneuroendocrino-
logy 2004;29:185–200.
30 Holsboer F: The corticosteroid receptor hy-
pothesis of depression. Neuropsychopharma-
cology 2000;23:477–501.
31 Heuser IJ, Schweiger U, Gotthardt U, Schmi-
der J, Lammers CH, Dettling M, Yassouridis
A, Holsboer F: Pituitary-adrenal-system regu-
lation and psychopathology during amitripty-
line treatment in elderly depressed patients and
normal comparison subjects. Am J Psychiatry
1996;153:93–99.
32 Casanueva FF, Dieguez C: Neuroendocrine
regulation and actions of leptin. Front Neu-
roendocrinol 1999;20:317–363.
33 Henry BA: Links between the appetite regulat-
ing systems and the neuroendocrine hypothala-
mus: Lessons from the sheep. J Neuroendocri-
nol 2003;15:697–709.
34 World Medical Association: Declaration of
Helsinki, ethical principles for medical re-
search involving human subjects. Ferney-Vol-
taire, WMA, 2000. http, //www.wma.net/e/pol-
icy/17-c_e.html.
35 Simpson GM: Principles and Techniques of
Applied Mathematics. New York, Fredman &
Wiley, 1956.
36 Piacentini MF, Meeusen R, Buyse L, De Schut-
ter G, Kempenaers F, Van Nijvel J, De Meir-
leir K: No effect of a noradrenergic reuptake
inhibitor on performance in trained cyclists.
Med Sci Sports Exerc 2002;34:1189–1193.
37 Hennig J, Lange N, Haag A, Rohrmann S, Net-
ter P: Reboxetine in a neuroendocrine chal-
lenge paradigm: Evidence for high cortisol re-
sponses in healthy volunteers scoring high on
subclinical depression. Int J Neuropsychophar-
macol 2000;3:193–201.
38 Hiwatari M, Johnston CI: Involvement of va-
sopressin in the cardiovascular effects of intra-
cerebroventricularly administered alpha 1-
adrenoceptor agonists in the conscious rat. J
Hypertens 1985;3:613–620.
39 Plotsky PM: Facilitation of immunoreactive
corticotropin-releasing factor secretion into the
hypophysial-portal circulation after activation
of catecholaminergic pathways or central nor-
epinephrine injection. Endocrinology 1987;
121:924–930.
40 Szafarczyk A, Malaval F, Laurent A, Gibaud R,
Assenmacher I: Further evidence for a central
stimulatory action of catecholamines on adre-
nocorticotropin release in the rat. Endocrinolo-
gy 1987;121:883–892.
41 Calogero AE, Gallucci WT, Chrousos GP,
Gold PW: Catecholamine effects upon rat hy-
pothalamic corticotropin-releasing hormone
secretion in vitro. J Clin Invest 1988;82:839–
846.
42 Hillhouse EW, Milton NG: Effect of noradren-
aline and gamma-aminobutyric acid on the se-
cretion of corticotrophin-releasing factor-41
and arginine vasopressin from the rat hypothal-
amus in vitro. J Endocrinol 1989;122:719–
723.
43 Al-Damluji S: Adrenergic control of the secre-
tion of anterior pituitary hormones. Baillieres
Clin Endocrinol Metab 1993;7:355–392.
44 Van Loon GR, Scapagnini U, Cohen R, Ga-
nong WF: Effect of intraventricular adminis-
tration of adrenergic drugs on the adrenal ve-
nous 17-hydroxycorticosteroid response to sur-
62 Neuroendocrinology 2004;79:54–62 Schüle/Baghai/Laakmann
gical stress in the dog. Neuroendocrinology
1971;8:257–272.
45 Ganong WF, Kramer N, Salmon J, Reid IA,
Lovinger R, Scapagnini U, Boryczka AT,
Shackelford R: Pharmacological evidence for
inhibition of ACTH secretion by a central
adrenergic system in the dog. Neuroscience
1976;1:167–174.
46 Laakmann G, Wittmann M, Schön HW, Zygan
K, Weiss A, Meissner R, Müller OA, Stalla GK:
Effects of receptor blockers (methysergide, pro-
pranolol, phentolamine, yohimbine and prazo-
sin) on desimipramine-induced pituitary hor-
mone stimulation in humans. III. Hypothalam-
ic-pituitary-adrenocortical axis. Psychoneu-
roendocrinology 1986;11:475–489.
47 Nickel T, Sonntag A, Schill J, Zobel AW, Ackl
N, Brunnauer A, Murck H, Ising M, Yassouri-
dis A, Steiger A, Zihl J, Holsboer F: Clinical
and neurobiological effects of tianeptine and
paroxetine in major depression. J Clin Psycho-
pharmacol 2003;23:155–168.
48 Asnis GM, Halbreich U, Rabinovich H, Ryan
ND, Sachar EJ, Nelson B, Puig-Antich J, Nova-
cenko H: The cortisol response to desipramine
in endogenous depressives and normal con-
trols: Preliminary findings. Psychiatry Res
1985;14:225–233.
49 Asnis GM, Wetzler S, Sanderson WC, Kahn
RS, van Praag HM: Functional interrelation-
ship of serotonin and norepinephrine: Cortisol
response to MCPP and DMI in patients with
panic disorder, patients with depression, and
normal control subjects. Psychiatry Res 1992;
43:65–76.
50 Asnis GM, Sanderson WC, van Praag HM:
Cortisol response to intramuscular desipra-
mine in patients with major depression and
normal control subjects: A replication study.
Psychiatry Res 1992;44:237–250.
51 Barden N, Reul JM, Holsboer F: Do antide-
pressants stabilize mood through actions on the
hypothalamic-pituitary-adrenocortical system?
Trends Neurosci 1995;18:6–11.
52 Nierenberg AA: Do some antidepressants work
faster than others? J Clin Psychiatry 2001;
62(suppl 15):22–25.
53 Bech P: Meta-analysis of placebo-controlled
trials with mirtazapine using the core items of
the Hamilton Depression Scale as evidence of a
pure antidepressive effect in the short-term
treatment of major depression. Int J Neuropsy-
chopharmacol 2001;4:337–345.
54 Thompson C: Onset of action of antidepres-
sants: Results of different analyses. Hum Psy-
chopharmacol 2002;17(suppl 1):S27–S32.
55 Szegedi A, Müller MJ, Anghelescu I, Klawe C,
Kohnen R, Benkert O: Early improvement un-
der mirtazapine and paroxetine predicts later
stable response and remission with high sensi-
tivity in patients with major depression. J Clin
Psychiatry 2003;64:413–420.
56 Kabayama Y, Kato Y, Murakami Y, Tanaka H,
Imura H: Stimulation by alpha-adrenergic
mechanisms of the secretion of growth hormone-
releasing factor (GRF) from perifused rat hypo-
thalamus. Endocrinology 1986;119:432–434.
57 Tsagarakis S, Ge F, Rees LH, Besser GM,
Grossmann A: Stimulation of alpha-adreno-
ceptors facilitates the release of growth hor-
mone-releasing hormone from rat hypothala-
mus in vitro. Endocrinology 1989;123:1962–
1969.
58 Miki N, Ono M, Shizume K: Evidence that
opiatergic and alpha-adrenergic mechanisms
stimulate rat growth hormone release via
growth hormone-releasing factor (GRF). Endo-
crinology 1984;114:1950–1952.
59 Ishikawa K, Kakegawa T, Suzuki M: Role of
the hypothalamic paraventricular nucleus in
the secretion of thyrotropin under adrenergic
and cold-stimulated conditions in the rat. En-
docrinology 1984;114:352–358.
60 Alba-Roth J, Losa M, Spiess Y, Schopohl J,
Müller OA, von Werder K: Interaction of cloni-
dine and GHRH on GH secretion in vivo and
in vitro. Clin Endocrinol 1989;30:485–491.
61 Lal S, Tolis G, Martin JB, Brown GM, Guyda
H: Effect of clonidine on growth hormone, pro-
lactin, luteinizing hormone, and thyroid-stimu-
lating hormone in the serum of normal men. J
Clin Endocrinol Metab 1975;41:827–832.
62 Matussek N, Ackenheil M, Hippius H, Müller
F, Schröder HT, Schultes H, Wasilewski B:
Effect of clonidine on growth hormone release
in psychiatric patients and controls. Psychiatry
Res 1980;2:25–36.
63 Valcavi R, Dieguez C, Page MD, Zini M, Ca-
soli P, Portioli I, Scanlon MF: Alpha-2-adren-
ergic pathways release growth hormone via a
non-GRF-dependent mechanism in normal
human subjects. Clin Endocrinol (Oxf) 1988;
29:309–316.
64 Devesa J, Arce V, Lois N, Tresguerres AF, Lima
L: Alpha-2-adrenergic agonism enhances the
growth hormone (GH) response to GH-releasing
hormone through an inhibition of hypothalamic
somatostatin release in normal men. J Clin En-
docrinol Metab 1990;71:1581–1588.
65 Blackard WG, Heidingsfelder SA: Adrenergic
receptor control mechanism for growth hor-
mone secretion. J Clin Invest 1968;47:1407–
1414.
66 Laakmann G, Wittmann M, Schön HW, Zygan
K, Weiss A, Meissner R, Müller OA, Stalla GK:
Effects of receptor blockers (methysergide, pro-
pranolol, phentolamine, yohimbine and prazo-
sin) on desimipramine-induced pituitary hor-
mone stimulation in humans. I. Growth hor-
mone. Psychoneuroendocrinology 1986;11:
447–461.
67 Schmidt ME, Risinger RC, Hauger RL,
Schoute JL, Henry M, Potter W: Responses to
– 2-adrenoceptor blockade by idazoxan in
healthy male and female volunteers. Psycho-
neuroendocrinology 1997;22:177–188.
68 Willoughby JO, Day TA, Menadue MF, Jer-
vois PM, Blessing WW: Adrenoceptors in the
preoptic-anterior hypothalamic area stimulate
secretion of prolactin but not growth hormone
in the male rat. Brain Res Bull 1986;16:697–
704.
69 Koshiyama H, Kato Y, Shimatsu A, Murakami
Y, Hattori N, Ishikawa Y, Imura H: Possible
involvement of endogenous opioid peptides in
prolactin secretion induced by alpha 2-adrener-
gic stimulation in rats. Proc Soc Exp Biol Med
1989;192:105–108.
70 Al-Damluji S: Measuring the activity of brain
adrenergic receptors with a neuroendocrine
marker. J Endocrinol 1989;123(suppl):abstr
44.
71 Saxton CA, Faulkner JK, Groom GV: The
effect on plasma prolactin, growth hormone
and luteinising hormone concentrations of sin-
gle oral doses or propranolol and tolamolol in
normal man. Eur J Clin Pharmacol 1981;21:
103–108.
72 Dart AM, McHardy K, Barber HE: The effect
of propranolol on luteinising hormone and pro-
lactin plasma concentrations in hypertensive
women. Br J Clin Pharmacol 1982;14:839–
841.
73 Lauridsen UB, Christensen NJ, Lyngsoe J: Ef-
fects of nonselective and beta-1-selective block-
ade on glucose metabolism and hormone re-
sponses during insulin-induced hypoglycemia
in normal man. J Clin Endocrinol Metab 1982;
56:876–882.
74 Goldberg MR, Jackson RV, Krakau J, Island
DP, Robertson D: Influence of yohimbine on
release of anterior pituitary hormones. Life Sci
1986;39:395–398.
75 Bouloux PMG; Grossmann A, Allolio B, Deli-
tala G, Besser GM: Effects of adrenergic antag-
onism on the growth hormone, prolactin and
cortisol response to a synthetic opioid agonist
in man. Horm Res 1986;23:83–90.
76 Al-Damluji S: Review: Adrenergic mechanisms
in the control of cortocotrophin secretion. J
Endocrinol 1988;119:5–14.
77 Karhuvaara S, Kallio A, Koulu M, Scheinin H,
Scheinin M: No involvement of alpha-2 adre-
noceptors in the regulation of basal prolactin
secretion in healthy man. Psychoneuroendocri-
nology 1990;15:125–129.
78 Lancranjan I, Marbach P: New evidence for
growth hormone modulation by the alpha-
adrenergic system in man. Metabolism 1977;
26:1225–1230.
79 Brambilla F, Lampertico M, Panerai AE, Sali
L, Salerno F, Muller EE: Effect of clonidine on
the secretion of anterior pituitary hormones in
heroin addicts and normal volunteers. Psychia-
try Res 1984;13:295–304.
80 Lechin F, van der Dijs B, Jakubowicz D, Ca-
mero RE, Villa S, Arocha L, Lechin AE: Effects
of clonidine on blood pressure, noradrenaline,
cortisol, growth hormone, and prolactin plas-
ma levels in high and low intestinal tone de-
pressed patients. Neuroendocrinology 1985;41:
156–162.
81 Krystal JH, Webb E, Cooney NL, Kranzler
HR, Southwick SW, Heninger GR, Charney
DS: Serotonergic and noradrenergic dysregula-
tion in alcoholism: m-Chlorophenylpiperazine
and yohimbine effects in recently detoxified
alcoholics and healthy comparison subjects.
Am J Psychiatry 1996;153:83–92.
82 Mokrani M, Duval F, Diep TS, Bailey PE,
Macher JP: Multihormonal responses to cloni-
dine in patients with affective and psychotic
symptoms. Psychoneuroendocrinology 2000;
25:741–52.
83 Cowen PJ, Anderson IM, Grahame-Smith DG:
Neuroendocrine effects of azapirones. J Clin
Psychopharmacol 1990;10:21S–25S.
